The ADO Knockout HT29 Polyclonal Cells are a robust CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma epithelial cell line. This product is generated via CRISPR/Cas9-mediated gene disruption of the ADO locus, yielding a heterogeneous pool of cells with targeted loss-of-function mutations. As polyclonal knockout cells, the population maintains genetic diversity while effectively abrogating ADO protein expression, providing a versatile toolkit for studying cysteamine metabolism and oxidative stress without the need for single-cell clones. The cells are free of antibiotic resistance cassettes, preserving native behaviors for downstream assays such as Western blotting, RT-qPCR, and metabolite quantification.
HT29 cells are a well-established human colorectal adenocarcinoma epithelial line originally derived from a 44-year-old Caucasian female. These cells retain key features of intestinal epithelium, including the capacity to form polarized monolayers and undergo differentiation into enterocyte- and goblet cell-like phenotypes, making them a preferred model for colorectal cancer biology, intestinal barrier function, and mucus secretion studies. Widely used in cancer research and drug screening, HT29 cells provide a physiologically relevant host for investigating how ADO disruption impacts colorectal cancer cell fitness and epithelial homeostasis.
The ADO gene encodes cysteamine (2-aminoethanethiol) dioxygenase, which catalyzes the Fe2?- and O?-dependent oxidation of cysteamine to hypotaurine, a direct precursor of the major antioxidant taurine. ADO expression is regulated by oxidative stress-responsive transcription factors NFE2L2 (NRF2), HIF1A, and ATF4. Within the taurine biosynthetic pathway, ADO functions upstream of hypotaurine dehydrogenase and the taurine transporter, while CDO1 and CSAD mediate parallel conversions in cysteine metabolism. ADO knockout disrupts cysteamine utilization, reducing hypotaurine and taurine levels, compromising cellular antioxidant capacity, and sensitizing cells to oxidative insults.
In the HT29 colorectal cancer context, ADO-mediated taurine production supports redox balance, proliferation, and survival under oxidative stress??hallmarks of colorectal carcinogenesis. The ADO knockout model enables dissection of endogenous cysteamine dioxygenase??s role in maintaining taurine pools and modulating responses to chemotherapeutic agents or reactive oxygen species. This system is particularly valuable for exploring connections between sulfur amino acid metabolism, oxidative stress-related disorders such as cystinosis and neurodegeneration, and colorectal cancer progression, offering insights into potential therapeutic vulnerabilities.
Applications include LC-MS-based quantification of hypotaurine and taurine, ROS detection assays, and viability assessments following cysteamine treatment or oxidative challenge. Western blotting and RT-qPCR confirm ADO disruption, while functional studies examine redox signaling, differentiation, and drug sensitivity. This polyclonal knockout population is well-suited for metabolic profiling in colorectal cancer, cystinosis drug mechanism research, and taurine biosynthesis pathway analysis. For further information or custom knockout requests, please contact Ascent Research.
